Videos

Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, Oncology Nursing News Co-Editor in Chief, shares her opinion on recent developments in leukemia treatment options.

Between monitoring for medication adherence and ensuring that patients know when to call if their symptoms escalate, oncology nurses are a pivotal factor in decreasing mortality among patients with leukemia, says Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN.

Chevon Rariy, MD, outlines patient eligibility criteria, and the alterations to the nurse patient relationship, as CTCA launches the novel Oncology Clinic at Home Program.

Nagla Abdel Karim, MD, explains how researchers will address safety and manage potential adverse events in the ongoing phase 3 CheckMate-73L trial.

“There were delays in getting preventative screenings, there were delay in diagnostics, there was also a brief period of time when some of the clinical trials were shut down.”

Nearly half of patients with gynecologic cancer reported financial distress as a result of the high costs of cancer treatment, yet money is still not commonly discussed between patients and providers.

Patients with gynecologic cancer are at higher risk for financial distress if they are enrolled in private insurance, are young in age, or are undergoing an employment change.

Kelly L. Garvin, BSN, RN, OCN, discusses what changes she hopes to see in CAR T-Cell therapy treatment over the coming years.

Proper training can help oncology nurses act as intensivists and quickly identify if their patients are experiencing any CAR T-cell therapy-related adverse events.

“This is a holistic, functional and integrative approach to your mental well-being. So, you start small, and you build up on that. It is not an overnight fix; it is a slow and steady progress.”

“More than 90% of serotonin receptors and serotonin is made in the gut.”

“When the pandemic hit, telehealth was well positioned to be a powerful tool. It really was the silver lining in the entire shift in care.”

The reality of the COVID-19 pandemic will force lawmakers to firmly act on behalf of antibiotic policies, according to an expert with Pew Charitable Trusts.

Despite significant concerns from many oncologists regarding the effects of drug resistant bacteria, many pharmaceutical companies have recently stopped developing antibiotics.

Oncology nurses are key players in helping patients with cancer find clinical trials, explained Martha Raymond, founder and CEO of the Raymond Foundation.

Now more than ever, it is important for new nurses to keep their head up and ensure that their voice is heard, according to Theresa Brown, RN.

Oncology providers reported having limited knowledge of the special concerns of LGBTQ patients, but wanted to know more.

Recent years have brought many changes to the treatment of patients with HER2-positive metastatic breast cancer.

Evaluating the benefits of the subQ vs IV formulation of the trastuzumab-pertuzumab combination for the management of HER2+ breast cancer and examining the potential use of at-home administration.

Clinicians should not be apprehensive to broach the topic of sexual health.

When the coronavirus disease 2019 (COVID-19) pandemic prevented Christie M. Santure, BSN, RN, OCN, from hosting her caregiver support group, she quickly adapted and switched to a virtual format.

Oncology nurses need to keep an eye out for diarrhea in their patients on CDK4/6 inhibitors.

Great men and women are forged through fire, so people who are passionate about health care should not put a nursing degree on hold because of the COVID-19 pandemic.

Small cell lung cancer is very sensitive to chemotherapy, but immunotherapy offers another line of treatment for when chemotherapy stops working.

A phase 3 trial designed to evaluate eprenetapopt plus azacytidine (Vidaza) in patients with TP53-mutant positive myelodysplastic syndrome (MDS) completed full enrollment, according to Aprea Therapeutics, Inc.

Oncology Nursing News sat down with Brian Rini, MD, from the Vanderbilt-Ingram Cancer Center (VICC), to discuss results from the phase III TIVO03 trial, and its potential impact on patients with relapsed or refractory renal cell carcinoma.